Meeting
2014 Gastrointestinal Cancers Symposium
Novel Kras-directed therapy in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.
Authors
Talia Golan
Sheba Medical Center, Tel HaShomer, Israel
Talia Golan , Ayala Hubert , Amotz Shemi , Amiel Segal , Elina Zorde Khvalevsky , Avi Domb , Eliel Ben-David , Stephen Raskin , Yuri Goldes , Maor Lahav , Alan Dancour , Eithan Galun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01188785
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 270)
DOI
10.1200/jco.2014.32.3_suppl.270
Abstract #
270
Poster Bd #
B43
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.
First Author: Talia Golan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOLFIRINOX plus high intensity focused ultrasound for locally advanced/borderline resectable pancreatic ductal adenocarcinoma: A prospective single arm phase II trial.
First Author: Dong Ho Lee
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang